Catalyst Pharmaceuticals (CPRX) Financials

$30.90 +1.96 (+6.77%)

Closing price 04:00 PM Eastern

Extended Trading

$30.62 -0.28 (-0.91%)

As of 05:22 PM Eastern

Annual Income Statements for Catalyst Pharmaceuticals

This table shows Catalyst Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-20	-18	-18	-34	32	75	39	83	71	164	214
Consolidated Net Income / (Loss)	-20	-18	-18	-34	32	75	39	83	71	164	214
Net Income / (Loss) Continuing Operations	-20	-18	-18	-34	32	75	39	83	71	164	214
Total Pre-Tax Income	-20	-18	-18	-34	33	42	53	105	95	216	284
Total Operating Income	-20	-19	-19	-35	32	41	52	102	87	195	258
Total Gross Profit	0.00	0.00	0.00	0.50	88	102	119	180	346	423	502
Total Revenue	0.00	0.00	0.00	0.50	102	119	141	214	398	492	589
Operating Revenue	0.00	0.00	0.00	0.50	102	119	141	214	398	492	589
Total Cost of Revenue	0.00	0.00	0.00	0.00	15	17	22	34	52	69	87
Operating Cost of Revenue	-	-	-	0.00	15	17	22	34	52	69	87
Total Operating Expenses	20	19	19	36	56	61	67	78	259	228	244
Selling, General & Admin Expense	8.60	7.91	7.30	16	37	44	50	57	134	178	194
Research & Development Expense	12	11	11	20	19	16	17	20	93	13	13
Amortization Expense	-	-	-	-	-	-	0.00	1.10	33	37	37
Total Other Income / (Expense), net	0.17	1.21	0.27	1.29	1.59	0.59	0.28	2.88	7.70	21	26
Other Income / (Expense), net	0.17	1.21	0.27	1.29	1.59	0.59	0.28	2.88	7.70	21	26
Income Tax Expense	0.00	0.00	0.00	0.00	1.53	-33	13	22	23	52	69
Basic Earnings per Share	($0.25)	($0.22)	($0.21)	($0.33)	$0.31	$0.72	$0.38	$0.80	$0.67	$1.38	$1.75
Weighted Average Basic Shares Outstanding	80.86M	82.88M	85.80M	102.63M	102.94M	103.51M	103.38M	103.37M	106.28M	118.46M	122.29M
Diluted Earnings per Share	($0.25)	($0.22)	($0.21)	($0.33)	$0.30	$0.71	$0.37	$0.75	$0.63	$1.31	$1.68
Weighted Average Diluted Shares Outstanding	80.86M	82.88M	85.80M	102.63M	106.02M	106.24M	107.80M	111.38M	113.75M	124.94M	127.26M
Weighted Average Basic & Diluted Shares Outstanding	80.86M	82.88M	85.80M	102.63M	103.41M	103.82M	102.74M	105.65M	117.86M	121.45M	122.12M

This table shows Catalyst Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	38	-31	35	23	41	44	56	57	52	53	53
Consolidated Net Income / (Loss)	38	-31	35	23	41	44	56	57	52	53	53
Net Income / (Loss) Continuing Operations	38	-31	35	23	41	44	56	57	52	53	53
Total Pre-Tax Income	49	-38	47	29	56	57	74	71	69	71	72
Total Operating Income	47	-37	42	27	54	51	63	63	66	66	62
Total Gross Profit	88	89	95	86	107	109	120	124	126	126	127
Total Revenue	100	103	111	99	123	129	142	141	147	148	153
Operating Revenue	100	103	111	99	123	129	142	141	147	148	153
Total Cost of Revenue	12	14	16	13	15	19	22	18	21	23	26
Operating Cost of Revenue	12	14	16	13	15	19	22	18	21	23	26
Total Operating Expenses	41	126	53	59	53	59	57	60	60	59	65
Selling, General & Admin Expense	28	34	42	47	41	46	44	47	46	47	53
Research & Development Expense	3.95	84	1.97	2.58	2.99	3.28	3.80	3.89	4.36	2.66	1.81
Amortization Expense	8.49	8.49	9.06	9.34	9.34	9.35	9.34	9.35	9.34	9.34	9.47
Total Other Income / (Expense), net	1.81	-0.83	5.02	1.96	1.54	6.30	11	7.92	3.00	4.77	10
Other Income / (Expense), net	1.81	-0.83	5.02	1.96	1.54	6.30	11	7.92	3.00	4.77	10
Income Tax Expense	11	-7.26	12	5.81	15	13	18	15	17	18	19
Basic Earnings per Share	$0.36	($0.29)	$0.32	$0.20	$0.35	$0.37	$0.46	$0.47	$0.43	$0.43	$0.42
Weighted Average Basic Shares Outstanding	106.26M	106.57M	106.28M	116.81M	118.18M	118.93M	118.46M	121.47M	122.16M	122.60M	122.29M
Diluted Earnings per Share	$0.33	($0.29)	$0.33	$0.19	$0.33	$0.35	$0.44	$0.45	$0.41	$0.42	$0.40
Weighted Average Diluted Shares Outstanding	113.67M	106.57M	113.75M	123.40M	124.66M	125.41M	124.94M	126.96M	127.54M	127.09M	127.26M
Weighted Average Basic & Diluted Shares Outstanding	106.58M	106.61M	117.86M	118.12M	118.69M	119.27M	121.45M	121.98M	122.39M	122.91M	122.12M

This table details how cash moves in and out of Catalyst Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	19	-14	44	-41	73	41	41	127	-161	380	192
Net Cash From Operating Activities	-18	-18	-14	-26	35	45	60	116	144	240	209
Net Cash From Continuing Operating Activities	-18	-18	-14	-26	35	45	60	116	144	240	209
Net Income / (Loss) Continuing Operations	-20	-18	-18	-34	32	75	39	83	71	164	214
Consolidated Net Income / (Loss)	-20	-18	-18	-34	32	75	39	83	71	164	214
Depreciation Expense	0.03	0.04	0.05	0.04	0.06	0.09	0.19	0.14	0.32	0.40	0.38
Amortization Expense	-	-	-	0.00	0.24	0.00	0.00	1.10	33	37	37
Non-Cash Adjustments To Reconcile Net Income	1.52	0.95	2.59	3.11	3.26	6.12	7.22	13	94	16	24
Changes in Operating Assets and Liabilities, net	0.66	-0.88	2.03	4.71	-0.82	-36	13	19	-55	22	-67
Net Cash From Investing Activities	-0.01	3.55	-0.00	-15	37	-5.01	-11	9.21	-294	-0.56	-0.06
Net Cash From Continuing Investing Activities	-0.01	3.55	-0.00	-15	37	-5.01	-11	9.21	-294	-0.56	-0.06
Purchase of Property, Plant & Equipment	-0.02	-0.10	-	-0.09	-0.02	-0.01	-1.02	-0.03	-0.23	-0.56	-0.06
Acquisitions	-	-	-	-	-	-	0.00	-10	-280	0.00	0.00
Sale and/or Maturity of Investments	0.02	-	-	22	72	5.00	0.00	19	0.00	0.00	0.00
Other Investing Activities, net	-0.00	3.72	-	-	-	0.00	0.00	0.00	-	0.00	0.00
Net Cash From Financing Activities	37	0.07	57	0.29	1.12	0.70	-8.14	1.69	-11	141	-17
Net Cash From Continuing Financing Activities	37	0.07	57	0.29	1.12	0.70	-8.14	1.69	-11	141	-17
Repurchase of Common Equity	-	-	-	-	0.00	0.00	-12	-6.91	0.00	-0.30	-25
Issuance of Common Equity	35	-	54	-	-	-	-	0.00	0.00	141	0.00
Other Financing Activities, net	2.29	0.07	3.58	0.29	1.12	0.70	3.95	8.60	-11	-0.04	8.31
Cash Interest Paid	-	-	-	-	-	-	0.00	0.00	0.71	1.40	0.47
Cash Income Taxes Paid	-	-	-	0.00	0.00	2.79	3.00	7.67	50	68	72

This table details how cash moves in and out of Catalyst Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	31	-58	17	173	65	67	75	63	72	37	19
Net Cash From Operating Activities	31	45	56	32	64	73	71	60	71	32	45
Net Cash From Continuing Operating Activities	31	45	56	32	64	73	71	60	71	32	45
Net Income / (Loss) Continuing Operations	38	-31	35	23	41	44	56	57	52	53	53
Consolidated Net Income / (Loss)	38	-31	35	23	41	44	56	57	52	53	53
Depreciation Expense	0.08	0.08	0.08	0.09	0.09	0.11	0.11	0.12	0.12	0.07	0.07
Amortization Expense	8.49	8.49	9.06	9.34	9.34	9.35	9.34	9.35	9.34	9.34	9.47
Non-Cash Adjustments To Reconcile Net Income	3.45	85	3.04	9.52	6.78	1.56	-1.61	3.12	11	7.34	2.23
Changes in Operating Assets and Liabilities, net	-19	-17	8.62	-10	7.13	18	7.10	-9.28	-1.39	-37	-20
Net Cash From Investing Activities	-	-93	-38	-0.20	-0.01	-0.26	-0.09	0.00	-0.03	-	-0.03
Net Cash From Continuing Investing Activities	-	-93	-38	-0.20	-0.01	-0.26	-0.09	0.00	-0.03	-	-0.03
Purchase of Property, Plant & Equipment	-	-0.06	-0.09	-0.20	-0.01	-0.26	-0.09	0.00	-0.03	-	-0.03
Net Cash From Financing Activities	-0.21	-10	-0.67	141	1.16	-5.97	4.43	3.06	0.87	4.65	-26
Net Cash From Continuing Financing Activities	-0.21	-10	-0.67	141	1.16	-5.97	4.43	3.06	0.87	4.65	-26
Repurchase of Common Equity	-	-	-	-0.30	-	-	-	0.00	-	-	-25
Other Financing Activities, net	-0.21	-10	-0.67	0.35	1.16	-5.97	4.43	3.06	0.87	4.65	-0.28
Cash Interest Paid	-	0.65	0.06	0.07	0.08	1.16	0.09	0.10	0.11	0.12	0.13
Cash Income Taxes Paid	-	14	8.80	0.00	-	18	17	0.64	39	16	17

This table presents Catalyst Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	60	42	85	60	112	192	238	376	470	851	1,104
Total Current Assets	60	41	85	55	111	159	210	321	219	624	894
Cash & Equivalents	28	14	57	17	90	130	171	298	138	518	709
Accounts Receivable	-	-	-	-	11	5.99	6.62	10	54	65	126
Inventories, net	-	-	0.00	0.06	1.96	4.65	7.87	6.81	16	20	37
Prepaid Expenses	1.50	1.05	1.17	1.65	4.35	8.33	4.35	5.17	13	21	21
Plant, Property, & Equipment, net	0.19	0.24	0.19	0.25	0.21	0.13	0.96	0.85	1.20	1.35	1.04
Total Noncurrent Assets	0.01	0.01	0.01	5.02	0.80	33	27	54	250	226	209
Long-Term Investments	-	-	0.00	5.01	-	-	-	0.00	16	22	23
Intangible Assets	-	-	-	-	-	-	0.00	32	194	157	132
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	0.00	33	24	19	37	46	53
Other Noncurrent Operating Assets	0.01	0.01	0.01	0.01	0.80	0.01	3.03	2.77	2.51	2.23	1.94
Total Liabilities & Shareholders' Equity	60	42	85	60	112	192	238	376	470	851	1,104
Total Liabilities	4.63	2.40	4.42	9.67	25	23	31	75	82	124	150
Total Current Liabilities	3.44	2.09	4.27	9.51	24	23	27	58	76	121	147
Accounts Payable	1.79	0.93	1.95	2.34	4.12	4.26	2.77	3.98	15	17	11
Accrued Expenses	1.65	1.16	2.32	7.17	20	19	24	54	61	104	136
Total Noncurrent Liabilities	1.18	0.30	0.16	0.15	0.65	0.00	3.89	18	6.17	3.10	2.56
Other Noncurrent Operating Liabilities	1.18	0.30	0.16	0.15	0.65	0.00	3.89	18	6.17	3.10	2.56
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	55	39	81	51	88	170	207	300	388	728	954
Total Preferred & Common Equity	55	39	81	51	88	170	207	300	388	728	954
Preferred Stock	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	55	39	81	51	88	170	207	300	388	728	954
Common Stock	146	147	208	211	216	223	233	251	267	442	480
Retained Earnings	-90	-108	-127	-161	-129	-54	-26	50	121	285	474
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-0.02	0.01	0.03	-0.15	0.02	0.01	0.06	0.00

This table presents Catalyst Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	333	407	444	413	647	706	772	909	972	1,052
Total Current Assets	276	199	241	192	405	474	539	686	759	852
Cash & Equivalents	256	148	179	121	310	376	442	581	653	690
Accounts Receivable	9.34	33	43	48	60	57	58	71	66	106
Inventories, net	7.13	10	11	9.04	20	18	20	20	19	28
Prepaid Expenses	3.78	6.93	8.63	14	14	24	18	14	21	28
Plant, Property, & Equipment, net	0.88	1.29	1.20	1.19	1.31	1.23	1.38	1.24	1.15	1.08
Total Noncurrent Assets	56	207	202	220	241	231	232	222	212	198
Long-Term Investments	-	-	-	13	15	13	15	24	21	19
Intangible Assets	33	184	176	167	185	175	166	147	138	129
Noncurrent Deferred & Refundable Income Taxes	20	20	23	37	38	40	48	48	51	48
Other Noncurrent Operating Assets	2.84	2.71	2.64	2.58	2.44	2.37	2.30	2.16	2.08	2.01
Total Liabilities & Shareholders' Equity	333	407	444	413	647	706	772	909	972	1,052
Total Liabilities	63	74	69	65	85	98	111	115	116	131
Total Current Liabilities	45	57	53	58	80	92	105	112	113	129
Accounts Payable	2.53	3.39	4.42	4.60	10	7.12	12	11	5.53	9.10
Accrued Expenses	42	53	48	53	69	85	94	100	107	120
Total Noncurrent Liabilities	18	17	16	6.86	5.70	5.39	5.67	2.94	2.88	2.62
Other Noncurrent Operating Liabilities	18	17	16	6.86	5.70	5.39	5.67	2.94	2.88	2.62
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	270	334	375	349	561	609	661	794	856	920
Total Preferred & Common Equity	270	334	375	349	561	609	661	794	856	920
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	270	334	375	349	561	609	661	794	856	920
Common Stock	246	254	258	262	417	423	432	452	462	473
Retained Earnings	24	79	117	86	145	185	229	342	394	447
Accumulated Other Comprehensive Income / (Loss)	0.03	0.01	0.02	0.02	0.00	0.00	0.00	-0.02	0.03	0.00

This table displays calculated financial ratios and metrics derived from Catalyst Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	20,361.20%	16.39%	18.27%	52.10%	85.90%	23.49%	19.78%
EBITDA Growth	-30.46%	10.74%	-1.87%	-84.93%	199.24%	24.55%	25.91%	100.45%	20.23%	99.41%	26.51%
EBIT Growth	-30.46%	10.68%	-1.88%	-84.68%	198.25%	25.39%	25.73%	98.83%	-9.75%	128.82%	31.10%
NOPAT Growth	-39.80%	5.48%	3.11%	-88.95%	222.89%	143.50%	-46.88%	105.74%	-18.81%	125.44%	31.79%
Net Income Growth	-30.46%	10.68%	-1.88%	-84.68%	193.74%	135.24%	-47.35%	110.42%	-14.05%	129.50%	30.78%
EPS Growth	-4.17%	12.00%	4.55%	-57.14%	190.91%	136.67%	-47.89%	102.70%	-16.00%	107.94%	28.24%
Operating Cash Flow Growth	-39.20%	0.29%	23.50%	-90.27%	232.37%	30.11%	34.06%	92.22%	23.74%	67.00%	-12.98%
Free Cash Flow Firm Growth	-81.07%	0.47%	27.39%	-80.26%	247.35%	27.68%	40.56%	77.90%	-276.12%	216.24%	-16.72%
Invested Capital Growth	27.59%	62.44%	-178.02%	-152.69%	10.61%	525.62%	-46.91%	-86.98%	11,437.81%	-19.35%	18.06%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	40.75%	0.75%	5.46%	11.71%	14.30%	6.79%	1.87%
EBITDA Q/Q Growth	-13.02%	8.42%	-7.17%	-36.63%	219.71%	-1.26%	10.18%	24.39%	21.14%	12.28%	-0.68%
EBIT Q/Q Growth	-12.98%	8.37%	-7.12%	-36.61%	218.06%	0.77%	8.42%	23.89%	16.95%	14.55%	-0.80%
NOPAT Q/Q Growth	-12.14%	8.87%	-6.85%	-35.94%	238.36%	81.69%	-5.00%	21.81%	12.54%	12.37%	-1.08%
Net Income Q/Q Growth	-12.98%	8.37%	-7.12%	-36.61%	237.44%	4.91%	-5.11%	24.15%	15.11%	14.77%	-1.49%
EPS Q/Q Growth	-8.70%	12.00%	-5.00%	-32.00%	233.33%	4.41%	-5.13%	22.95%	18.87%	9.17%	-2.33%
Operating Cash Flow Q/Q Growth	-3.75%	1.21%	2.70%	-19.80%	147.79%	1.84%	11.18%	21.97%	12.16%	6.78%	-11.07%
Free Cash Flow Firm Q/Q Growth	-0.96%	-0.25%	6.54%	-12.99%	197.29%	396.22%	12.85%	23.76%	-16.65%	35.51%	-15.17%
Invested Capital Q/Q Growth	-26.27%	40.42%	-40.06%	-195.66%	-92.90%	-0.67%	-34.79%	-85.50%	8.89%	-7.49%	5.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	100.00%	85.57%	85.69%	84.46%	83.94%	86.95%	86.00%	85.19%
EBITDA Margin	0.00%	0.00%	0.00%	-6,793.11%	32.95%	35.26%	37.53%	49.47%	31.99%	51.66%	54.57%
Operating Margin	0.00%	0.00%	0.00%	-7,059.03%	31.11%	34.69%	37.20%	47.54%	21.80%	39.68%	43.77%
EBIT Margin	0.00%	0.00%	0.00%	-6,800.70%	32.66%	35.18%	37.40%	48.89%	23.73%	43.98%	48.14%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	-6,800.70%	31.16%	62.97%	28.03%	38.79%	17.93%	33.33%	36.39%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	95.41%	179.00%	74.97%	79.34%	75.56%	75.78%	75.60%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	4.59%	-79.00%	25.03%	20.66%	24.44%	24.22%	24.40%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	659.19%	174.98%	918.58%	55.64%	70.04%	94.81%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	658.30%	174.86%	917.64%	53.07%	65.41%	91.75%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	-600.89%	-154.01%	-885.82%	-34.89%	-40.65%	-69.32%
Return on Equity (ROE)	-44.61%	-38.13%	-30.62%	-51.62%	46.06%	58.30%	20.98%	32.76%	20.75%	29.38%	25.49%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	128.66%	236.27%	1,072.51%	-140.92%	91.46%	78.25%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-46.63%	38.66%	27.49%	24.49%	34.14%	22.35%	32.73%	29.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-46.63%	36.89%	49.21%	18.36%	27.09%	16.89%	24.80%	21.92%
Return on Common Equity (ROCE)	-44.61%	-38.13%	-30.62%	-51.62%	46.06%	58.30%	20.98%	32.76%	20.75%	29.38%	25.49%
Return on Equity Simple (ROE_SIMPLE)	-36.47%	-45.98%	-22.74%	-66.96%	36.37%	44.21%	19.09%	27.65%	18.41%	22.52%	0.00%
Net Operating Profit after Tax (NOPAT)	-14	-13	-13	-25	30	74	39	81	66	148	195
NOPAT Margin	0.00%	0.00%	0.00%	-4,941.32%	29.68%	62.09%	27.88%	37.72%	16.47%	30.07%	33.09%
Net Nonoperating Expense Percent (NNEP)	-12.19%	-9.26%	-8.58%	-13.05%	1.98%	0.90%	0.13%	0.93%	2.57%	4.62%	3.06%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	26.89%	16.91%	20.32%	20.42%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	14.43%	14.31%	15.54%	16.06%	13.05%	14.00%	14.81%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	3,175.19%	36.05%	37.15%	35.24%	26.65%	33.58%	36.15%	32.90%
R&D to Revenue	0.00%	0.00%	0.00%	3,983.84%	18.42%	13.85%	12.03%	9.24%	23.39%	2.57%	2.16%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	7,159.03%	54.47%	51.00%	47.26%	36.40%	65.15%	46.32%	41.42%
Earnings before Interest and Taxes (EBIT)	-20	-18	-18	-34	33	42	53	105	95	216	284
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-20	-18	-18	-34	34	42	53	106	127	254	321
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.66	2.21	4.12	3.88	4.41	2.04	3.38	6.44	4.62	3.42	3.01
Price to Tangible Book Value (P/TBV)	3.66	2.21	4.12	3.88	4.41	2.04	3.38	7.22	9.25	4.36	3.49
Price to Revenue (P/Rev)	0.00	0.00	0.00	394.52	3.78	2.91	4.96	9.04	4.50	5.06	4.87
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	12.12	4.62	17.68	23.30	25.10	15.19	13.39
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	8.25%	21.66%	5.66%	4.29%	3.98%	6.58%	7.47%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	7.02	32.56	808.16	7.01	10.34	9.60
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	277.54	2.85	1.73	3.60	7.64	4.11	3.97	3.63
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	8.66	4.90	9.59	15.45	12.86	7.68	6.65
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	8.74	4.92	9.62	15.64	17.33	9.02	7.54
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	9.61	2.79	12.91	20.27	24.97	13.19	10.97
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	8.43	4.57	8.40	14.11	11.41	8.13	10.24
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	9.88	5.46	9.56	17.36	0.00	10.10	13.29
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.08	-1.04	-1.03	-1.08	-1.11	-0.91	-0.88	-0.97	-0.66	-0.62	-0.76
Leverage Ratio	1.15	1.07	1.06	1.11	1.25	1.18	1.14	1.21	1.23	1.18	1.16
Compound Leverage Factor	1.15	1.07	1.06	1.11	1.25	1.18	1.14	1.21	1.23	1.18	1.16
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	24.24	17.84	43.55	7.58	10.59	10.93	15.62	17.96	15.31	14.66	14.29
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	17.41	19.79	19.97	5.80	4.62	7.00	7.76	5.57	2.88	5.17	6.08
Quick Ratio	16.97	19.29	19.69	5.62	4.36	6.43	7.31	5.36	2.51	4.83	5.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-15	-15	-11	-20	30	38	53	94	-166	193	161
Operating Cash Flow to CapEx	-76,774.86%	-18,700.10%	0.00%	-28,415.69%	182,168.42%	409,400.00%	5,913.03%	400,162.07%	62,164.50%	43,130.94%	359,775.86%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.01	1.18	0.78	0.65	0.70	0.94	0.74	0.60
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	14.41	22.34	25.11	12.45	8.27	6.14
Inventory Turnover	0.00	0.00	0.00	0.00	14.67	5.16	3.50	4.69	4.63	3.91	3.08
Fixed Asset Turnover	0.00	0.00	0.00	2.29	448.82	699.47	258.65	237.21	390.01	385.83	492.67
Accounts Payable Turnover	0.00	0.00	0.00	0.00	4.57	4.07	6.23	10.20	5.54	4.39	6.28
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	25.33	16.34	14.53	29.31	44.16	59.48
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	24.89	70.77	104.42	77.87	78.84	93.27	118.61
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	79.82	89.69	58.58	35.78	65.92	83.21	58.14
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	-54.93	6.41	62.18	56.62	42.23	54.23	119.95
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-2.92	-1.10	-3.05	-7.71	-6.89	29	16	2.03	234	189	223
Invested Capital Turnover	0.00	0.00	0.00	-0.09	-14.02	10.62	6.28	24.35	3.38	2.33	2.87
Increase / (Decrease) in Invested Capital	1.11	1.82	-1.95	-4.66	0.82	36	-14	-14	232	-45	34
Enterprise Value (EV)	145	47	249	139	292	206	507	1,637	1,638	1,950	2,137
Market Capitalization	203	87	333	197	386	346	698	1,936	1,792	2,489	2,869
Book Value per Share	$0.67	$0.47	$0.95	$0.49	$0.85	$1.64	$2.01	$2.89	$3.64	$6.10	$7.76
Tangible Book Value per Share	$0.67	$0.47	$0.95	$0.49	$0.85	$1.64	$2.01	$2.57	$1.82	$4.79	$6.69
Total Capital	55	39	81	51	88	170	207	300	388	728	954
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-58	-40	-84	-58	-95	-140	-191	-298	-154	-539	-732
Capital Expenditures (CapEx)	0.02	0.10	0.00	0.09	0.02	0.01	1.02	0.03	0.23	0.56	0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.94	-1.05	-3.09	-7.81	-7.25	-3.79	-8.22	-35	5.63	-15	38
Debt-free Net Working Capital (DFNWC)	56	39	81	46	87	136	183	263	143	503	747
Net Working Capital (NWC)	56	39	81	46	87	136	183	263	143	503	747
Net Nonoperating Expense (NNE)	5.95	4.58	5.34	9.30	-1.51	-1.05	-0.21	-2.29	-5.82	-16	-19
Net Nonoperating Obligations (NNO)	-58	-40	-84	-58	-95	-140	-191	-298	-154	-539	-732
Total Depreciation and Amortization (D&A)	0.03	0.04	0.05	0.04	0.30	0.09	0.19	1.24	33	38	38
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-1,561.11%	-7.09%	-3.18%	-5.84%	-16.42%	1.41%	-2.97%	6.40%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	9,135.21%	85.30%	114.63%	129.97%	122.88%	35.98%	102.28%	126.81%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	9,135.21%	85.30%	114.63%	129.97%	122.88%	35.98%	102.28%	126.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.25)	($0.22)	($0.21)	($0.33)	$0.31	$0.72	$0.38	$0.80	$0.67	$1.38	$1.75
Adjusted Weighted Average Basic Shares Outstanding	82.88M	82.97M	102.56M	102.74M	102.94M	103.51M	103.38M	103.37M	106.28M	118.46M	122.29M
Adjusted Diluted Earnings per Share	($0.25)	($0.22)	($0.21)	($0.33)	$0.30	$0.71	$0.37	$0.75	$0.63	$1.31	$1.68
Adjusted Weighted Average Diluted Shares Outstanding	82.88M	82.97M	102.56M	102.74M	106.02M	106.24M	107.80M	111.38M	113.75M	124.94M	127.26M
Adjusted Basic & Diluted Earnings per Share	($0.25)	($0.22)	($0.21)	($0.33)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	80.86M	82.88M	85.80M	102.63M	103.41M	103.82M	102.74M	105.65M	117.86M	121.45M	122.12M
Normalized Net Operating Profit after Tax (NOPAT)	-14	-13	-13	-25	30	29	39	81	66	148	195
Normalized NOPAT Margin	0.00%	0.00%	0.00%	-4,941.32%	29.68%	24.28%	27.88%	37.72%	16.47%	30.07%	33.09%
Pre Tax Income Margin	0.00%	0.00%	0.00%	-6,800.70%	32.66%	35.18%	37.40%	48.89%	23.73%	43.98%	48.14%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	30.62%	8.31%	0.00%	0.18%	11.80%

This table displays calculated financial ratios and metrics derived from Catalyst Pharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	87.49%	79.39%	81.98%	15.40%	23.23%	25.33%	28.27%	43.56%	19.44%	15.31%	7.61%
EBITDA Growth	101.83%	-210.89%	66.11%	-12.28%	14.26%	326.31%	49.76%	109.63%	20.74%	20.70%	-2.63%
EBIT Growth	71.75%	-246.20%	41.50%	-22.04%	15.00%	250.46%	58.82%	145.06%	24.21%	24.18%	-3.07%
NOPAT Growth	66.24%	-218.56%	30.86%	-23.08%	9.12%	250.03%	52.36%	132.37%	25.69%	26.08%	-4.34%
Net Income Growth	74.67%	-235.24%	36.80%	-21.28%	8.03%	242.65%	60.53%	143.77%	27.73%	20.28%	-5.79%
EPS Growth	65.00%	-245.00%	43.48%	-26.92%	0.00%	220.69%	33.33%	136.84%	24.24%	20.00%	-9.09%
Operating Cash Flow Growth	17.42%	9.27%	38.85%	164.50%	108.54%	61.48%	27.37%	88.08%	11.17%	-55.49%	-36.66%
Free Cash Flow Firm Growth	-496.95%	-811.90%	-637.77%	78.83%	111.65%	122.04%	146.17%	438.75%	438.61%	-16.30%	-87.82%
Invested Capital Growth	867.82%	1,436.06%	11,437.81%	27.10%	11.89%	-5.08%	-19.35%	-19.62%	-17.24%	3.64%	18.06%
Revenue Q/Q Growth	16.65%	3.12%	7.67%	-10.91%	24.57%	4.88%	10.20%	-0.28%	3.64%	1.25%	2.84%
EBITDA Q/Q Growth	29.99%	-151.60%	289.62%	-31.03%	69.33%	2.20%	25.48%	-3.46%	-2.47%	2.16%	1.23%
EBIT Q/Q Growth	30.01%	-178.37%	222.85%	-37.72%	91.78%	2.54%	29.68%	-3.90%	-2.80%	2.51%	1.22%
NOPAT Q/Q Growth	28.82%	-171.61%	219.48%	-30.22%	82.76%	-1.54%	21.34%	6.43%	-1.15%	-1.23%	-7.94%
Net Income Q/Q Growth	27.71%	-181.47%	213.26%	-33.20%	75.27%	7.57%	27.46%	1.43%	-8.16%	1.30%	-0.16%
EPS Q/Q Growth	26.92%	-187.88%	213.79%	-42.42%	73.68%	6.06%	25.71%	2.27%	-8.89%	2.44%	-4.76%
Operating Cash Flow Q/Q Growth	154.80%	46.74%	23.31%	-42.63%	100.89%	13.62%	-2.74%	-15.29%	18.74%	-54.50%	38.39%
Free Cash Flow Firm Q/Q Growth	-3.77%	-62.13%	11.51%	85.78%	157.10%	206.65%	85.38%	4.37%	-9.21%	-52.35%	-73.02%
Invested Capital Q/Q Growth	5.98%	9.25%	8.89%	0.81%	-6.69%	-7.33%	-7.49%	0.48%	-3.93%	16.05%	5.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.90%	86.20%	85.70%	87.29%	87.45%	85.02%	84.74%	87.34%	85.94%	84.73%	82.92%
EBITDA Margin	57.32%	-28.68%	50.51%	39.10%	53.15%	51.79%	58.98%	57.10%	53.73%	54.22%	53.36%
Operating Margin	46.90%	-36.21%	37.71%	27.54%	44.21%	39.56%	44.31%	44.81%	45.24%	44.66%	40.52%
EBIT Margin	48.72%	-37.03%	42.24%	29.53%	45.46%	44.45%	52.31%	50.41%	47.28%	47.87%	47.11%
Profit (Net Income) Margin	37.92%	-29.96%	31.51%	23.63%	33.24%	34.10%	39.44%	40.12%	35.55%	35.57%	34.53%
Tax Burden Percent	77.84%	80.91%	74.60%	80.01%	73.12%	76.71%	75.40%	79.59%	75.20%	74.31%	73.29%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	22.16%	0.00%	25.40%	19.99%	26.88%	23.29%	24.60%	20.41%	24.80%	25.69%	26.71%
Return on Invested Capital (ROIC)	102.01%	-77.25%	95.02%	43.05%	67.46%	66.79%	77.82%	89.71%	94.55%	92.47%	85.11%
ROIC Less NNEP Spread (ROIC-NNEP)	101.31%	-74.82%	93.36%	42.39%	67.06%	65.15%	75.35%	88.36%	94.13%	91.87%	83.95%
Return on Net Nonoperating Assets (RNNOA)	-65.67%	47.17%	-61.38%	-22.45%	-38.68%	-38.15%	-46.83%	-60.65%	-68.30%	-67.76%	-63.43%
Return on Equity (ROE)	36.34%	-30.08%	33.64%	20.60%	28.78%	28.64%	30.99%	29.06%	26.25%	24.72%	21.68%
Cash Return on Invested Capital (CROIC)	-60.83%	-124.57%	-140.92%	4.21%	18.82%	68.11%	91.46%	104.88%	111.82%	91.37%	78.25%
Operating Return on Assets (OROA)	41.50%	-34.57%	39.78%	23.05%	34.34%	34.54%	38.93%	34.65%	31.47%	30.36%	28.38%
Return on Assets (ROA)	32.31%	-27.97%	29.68%	18.44%	25.11%	26.50%	29.35%	27.58%	23.66%	22.56%	20.80%
Return on Common Equity (ROCE)	36.34%	-30.08%	33.64%	20.60%	28.78%	28.64%	30.99%	29.06%	26.25%	24.72%	21.68%
Return on Equity Simple (ROE_SIMPLE)	30.79%	17.80%	0.00%	11.60%	11.20%	21.61%	0.00%	24.85%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	36	-26	31	22	40	39	47	50	50	49	45
NOPAT Margin	36.50%	-25.35%	28.13%	22.03%	32.33%	30.35%	33.41%	35.66%	34.02%	33.18%	29.70%
Net Nonoperating Expense Percent (NNEP)	0.71%	-2.43%	1.65%	0.66%	0.40%	1.63%	2.47%	1.35%	0.42%	0.61%	1.16%
Return On Investment Capital (ROIC_SIMPLE)	-	-	8.02%	-	-	-	6.51%	6.35%	5.82%	5.35%	4.75%
Cost of Revenue to Revenue	12.10%	13.80%	14.30%	12.71%	12.55%	14.98%	15.26%	12.67%	14.06%	15.27%	17.09%
SG&A Expenses to Revenue	28.52%	32.68%	38.02%	47.65%	33.19%	35.65%	31.16%	33.17%	31.35%	31.99%	35.00%
R&D to Revenue	3.97%	81.47%	1.78%	2.62%	2.43%	2.55%	2.68%	2.75%	2.97%	1.79%	1.18%
Operating Expenses to Revenue	41.01%	122.42%	47.99%	59.75%	43.24%	45.46%	40.43%	42.53%	40.70%	40.08%	42.39%
Earnings before Interest and Taxes (EBIT)	49	-38	47	29	56	57	74	71	69	71	72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	57	-29	56	39	65	67	84	81	79	80	81
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.80	3.57	4.62	3.03	3.01	3.57	3.42	3.71	3.09	2.62	3.01
Price to Tangible Book Value (P/TBV)	7.14	6.87	9.25	4.51	4.22	4.77	4.36	4.55	3.69	3.05	3.49
Price to Revenue (P/Rev)	4.71	3.58	4.50	4.13	4.21	5.12	5.06	5.51	4.74	4.17	4.87
Price to Earnings (P/E)	12.34	20.08	25.10	26.10	26.85	16.52	15.19	14.92	12.68	11.08	13.39
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	8.10%	4.98%	3.98%	3.83%	3.72%	6.05%	6.58%	6.70%	7.88%	9.02%	7.47%
Enterprise Value to Invested Capital (EV/IC)	6.35	5.18	7.01	5.83	6.55	9.34	10.34	12.36	10.84	8.06	9.60
Enterprise Value to Revenue (EV/Rev)	4.12	3.19	4.11	3.34	3.32	4.13	3.97	4.38	3.53	2.94	3.63
Enterprise Value to EBITDA (EV/EBITDA)	7.74	10.57	12.86	11.26	11.07	8.41	7.68	7.90	6.37	5.26	6.65
Enterprise Value to EBIT (EV/EBIT)	8.61	13.76	17.33	15.92	15.40	10.08	9.02	9.05	7.25	5.96	7.54
Enterprise Value to NOPAT (EV/NOPAT)	11.31	19.08	24.97	23.24	23.03	14.46	13.19	13.25	10.56	8.64	10.97
Enterprise Value to Operating Cash Flow (EV/OCF)	10.04	8.69	11.41	8.40	7.32	8.47	8.13	8.73	7.17	7.25	10.24
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	154.87	36.78	13.35	10.10	10.50	8.78	8.98	13.29
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.65	-0.63	-0.66	-0.53	-0.58	-0.59	-0.62	-0.69	-0.73	-0.74	-0.76
Leverage Ratio	1.15	1.21	1.23	1.18	1.17	1.17	1.18	1.15	1.15	1.15	1.16
Compound Leverage Factor	1.15	1.21	1.23	1.18	1.17	1.17	1.18	1.15	1.15	1.15	1.16
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	14.39	12.78	14.98	13.66	13.13	14.68	14.11	17.55	15.88	13.21	13.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.59	3.32	2.88	5.09	5.14	5.11	5.17	6.14	6.71	6.62	6.08
Quick Ratio	4.22	2.92	2.51	4.66	4.69	4.75	4.83	5.84	6.36	6.19	5.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-140	-227	-201	-29	16	50	93	97	88	42	11
Operating Cash Flow to CapEx	0.00%	70,512.50%	59,836.56%	16,042.71%	641,350.00%	28,135.52%	80,542.05%	0.00%	274,223.08%	0.00%	140,284.38%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.85	0.93	0.94	0.78	0.76	0.78	0.74	0.69	0.67	0.63	0.60
Accounts Receivable Turnover	11.57	12.14	12.45	8.76	8.69	8.66	8.27	8.12	9.08	7.02	6.14
Inventory Turnover	4.61	5.86	4.63	3.60	4.03	4.34	3.91	3.74	4.33	3.45	3.08
Fixed Asset Turnover	285.80	336.94	390.01	317.28	357.59	358.91	385.83	419.82	470.12	470.65	492.67
Accounts Payable Turnover	12.72	13.29	5.54	7.99	10.04	7.80	4.39	6.92	12.57	8.02	6.28
Days Sales Outstanding (DSO)	31.56	30.06	29.31	41.66	41.99	42.14	44.16	44.98	40.20	51.98	59.48
Days Inventory Outstanding (DIO)	79.22	62.31	78.84	101.32	90.67	84.14	93.27	97.67	84.22	105.87	118.61
Days Payable Outstanding (DPO)	28.69	27.47	65.92	45.68	36.36	46.81	83.21	52.75	29.05	45.52	58.14
Cash Conversion Cycle (CCC)	82.09	64.90	42.23	97.30	96.29	79.47	54.23	89.90	95.38	112.33	119.95
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	197	215	234	236	220	204	189	189	182	211	223
Invested Capital Turnover	2.79	3.05	3.38	1.95	2.09	2.20	2.33	2.52	2.78	2.79	2.87
Increase / (Decrease) in Invested Capital	176	201	232	50	23	-11	-45	-46	-38	7.42	34
Enterprise Value (EV)	1,247	1,112	1,638	1,374	1,441	1,902	1,950	2,340	1,973	1,702	2,137
Market Capitalization	1,426	1,246	1,792	1,699	1,830	2,360	2,489	2,945	2,647	2,411	2,869
Book Value per Share	$3.54	$3.27	$3.64	$4.81	$5.15	$5.57	$6.10	$6.54	$7.02	$7.52	$7.76
Tangible Book Value per Share	$1.88	$1.70	$1.82	$3.23	$3.67	$4.17	$4.79	$5.33	$5.89	$6.47	$6.69
Total Capital	375	349	388	561	609	661	728	794	856	920	954
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-179	-134	-154	-326	-389	-457	-539	-605	-674	-709	-732
Capital Expenditures (CapEx)	0.00	0.06	0.09	0.20	0.01	0.26	0.09	0.00	0.03	0.00	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	9.68	13	5.63	15	6.42	-8.73	-15	-6.59	-7.07	34	38
Debt-free Net Working Capital (DFNWC)	188	134	143	325	382	434	503	574	646	724	747
Net Working Capital (NWC)	188	134	143	325	382	434	503	574	646	724	747
Net Nonoperating Expense (NNE)	-1.41	4.73	-3.74	-1.57	-1.13	-4.83	-8.55	-6.30	-2.25	-3.54	-7.37
Net Nonoperating Obligations (NNO)	-179	-134	-154	-326	-389	-457	-539	-605	-674	-709	-732
Total Depreciation and Amortization (D&A)	8.57	8.57	9.14	9.43	9.44	9.45	9.46	9.46	9.46	9.42	9.54
Debt-free, Cash-free Net Working Capital to Revenue	3.19%	3.80%	1.41%	3.56%	1.48%	-1.90%	-2.97%	-1.23%	-1.27%	5.85%	6.40%
Debt-free Net Working Capital to Revenue	62.21%	38.52%	35.98%	79.02%	87.95%	94.16%	102.28%	107.37%	115.62%	125.17%	126.81%
Net Working Capital to Revenue	62.21%	38.52%	35.98%	79.02%	87.95%	94.16%	102.28%	107.37%	115.62%	125.17%	126.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.36	($0.29)	$0.32	$0.20	$0.35	$0.37	$0.46	$0.47	$0.43	$0.43	$0.42
Adjusted Weighted Average Basic Shares Outstanding	106.26M	106.57M	106.28M	116.81M	118.18M	118.93M	118.46M	121.47M	122.16M	122.60M	122.29M
Adjusted Diluted Earnings per Share	$0.33	($0.29)	$0.33	$0.19	$0.33	$0.35	$0.44	$0.45	$0.41	$0.42	$0.40
Adjusted Weighted Average Diluted Shares Outstanding	113.67M	106.57M	113.75M	123.40M	124.66M	125.41M	124.94M	126.96M	127.54M	127.09M	127.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.58M	106.61M	117.86M	118.12M	118.69M	119.27M	121.45M	121.98M	122.39M	122.91M	122.12M
Normalized Net Operating Profit after Tax (NOPAT)	36	-26	31	22	40	39	47	50	50	49	45
Normalized NOPAT Margin	36.50%	-25.35%	28.13%	22.03%	32.33%	30.35%	33.41%	35.66%	34.02%	33.18%	29.70%
Pre Tax Income Margin	48.72%	-37.03%	42.24%	29.53%	45.46%	44.45%	52.31%	50.41%	47.28%	47.87%	47.11%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.45%	0.43%	0.21%	0.18%	0.00%	0.00%	0.00%	11.80%

Financials Breakdown Chart

Key Financial Trends

Here are the key trends for Catalyst Pharmaceuticals (NASDAQ: CPRX) drawn from the last four years of quarterly statements. The focus is on notable movements in revenue, profitability, liquidity, and capital allocation.

Strong revenue growth and margin stability: Operating revenue rose from about $60.8 million in 2022 Q4 to $152.6 million in 2025 Q4, with gross margin consistently in the mid-to-high 80s% (roughly 83–85%).
Net income growth over the period: Net income attributable to common shareholders increased from roughly $25.5 million in 2022 Q4 to about $52.7 million in 2025 Q4, indicating meaningful earnings expansion alongside revenue gains.
Solid cash position and liquidity: Cash & equivalents climbed from around $256 million (2022 Q3) to approximately $690 million (2025 Q3), providing substantial liquidity to fund operations, capex (where applicable), and potential strategic moves.
Healthy operating cash flow: Net cash from continuing operating activities was consistently positive in 2025, with quarterly figures around $60–$72 million in early 2025 and $32–$45 million in later quarters, underscoring strong cash generation from core operations.
Very strong balance sheet and solvency: Total equity consistently sits well above total liabilities (e.g., ~\$794–\$920 million in 2025 across quarters), and current assets dramatically exceed current liabilities, yielding a robust liquidity cushion (current ratio well above 4x, often around 6–7x in recent quarters).
Capital return activity: Repurchase of common equity occurred in 2025 Q4 (approximately \$25.3 million), signaling management’s willingness to return capital to shareholders and potentially support valuation.
R&D intensity improving relative to revenue: Research & Development expense declined as a percentage of revenue in 2025 versus prior years (e.g., 1–2% of revenue in 2025 vs higher in earlier years), suggesting improved efficiency in the company’s R&D spend.
Past restatements and quarterly volatility: The company has noted restatements in earlier periods (e.g., 2023 Q4 restated and 2024 Q1 restated). While the current data reflects a cleaned-up baseline, investors should consider historical revisions when evaluating trend reliability.
Expense mix pressures on margins: Selling, General & Administrative (SG&A) expense rose in absolute terms relative to revenue (SG&A around 35% of revenue in 2025 Q4 vs roughly 31% in 2024 Q4), which can compress margin even as revenue grows.
Earnings per share show some quarterly volatility: Diluted earnings per share in 2025 Q4 (~$0.40) is slightly below the prior-year quarter (2024 Q4 around $0.44), despite stronger top-line growth. This indicates near-term EPS pressure or mix effects even as net income expands.
Quarterly variability in quarterly profitability: While trailing four-quarter trends are positive, quarterly pushes and pulls (e.g., lower Q3 2025 EPS vs Q4 2024) suggest near-term earnings volatility that investors may want to monitor as the pipeline and product mix evolve.

05/05/26 04:40 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Catalyst Pharmaceuticals' Financials

When does Catalyst Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Catalyst Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Catalyst Pharmaceuticals' net income changed over the last 10 years?

Catalyst Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $214.33 million in 2025, falling from -$20.23 million in 2015. The previous period was $163.89 million in 2024. See where experts think Catalyst Pharmaceuticals is headed by visiting Catalyst Pharmaceuticals' forecast page.

What is Catalyst Pharmaceuticals' operating income?

Catalyst Pharmaceuticals' total operating income in 2025 was $257.78 million, based on the following breakdown:

Total Gross Profit: $501.74 million
Total Operating Expenses: $243.96 million

How has Catalyst Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, Catalyst Pharmaceuticals' total revenue changed from $0.00 in 2015 to $588.99 million in 2025, a change of 58,898,900,000.0%.

How much debt does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals' total liabilities were at $149.71 million at the end of 2025, a 21.0% increase from 2024, and a 3,136.8% increase since 2015.

How much cash does Catalyst Pharmaceuticals have?

In the past 10 years, Catalyst Pharmaceuticals' cash and equivalents has ranged from $13.89 million in 2016 to $709.17 million in 2025, and is currently $709.17 million as of their latest financial filing in 2025.

How has Catalyst Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Catalyst Pharmaceuticals' book value per share changed from 0.67 in 2015 to 7.76 in 2025, a change of 1,059.1%.

Related Companies

Financial statements for NASDAQ:CPRX last updated on 2/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Catalyst Pharmaceuticals (CPRX) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Catalyst Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Catalyst Pharmaceuticals (CPRX) Financials

Annual Income Statements for Catalyst Pharmaceuticals

Quarterly Income Statements for Catalyst Pharmaceuticals

Annual Cash Flow Statements for Catalyst Pharmaceuticals

Quarterly Cash Flow Statements for Catalyst Pharmaceuticals

Annual Balance Sheets for Catalyst Pharmaceuticals

Quarterly Balance Sheets for Catalyst Pharmaceuticals

Annual Metrics And Ratios for Catalyst Pharmaceuticals

Quarterly Metrics And Ratios for Catalyst Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Catalyst Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools